nach oben

Der Nervenarzt

Erschienen in:

01.08.2007 | Übersichten

Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen

verfasst von: C. Kleinschnitz, S.G. Meuth, B.C. Kieseier, Prof. Dr. H. Wiendl

Erschienen in: Der Nervenarzt | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Multiple Sklerose (MS) ist eine chronische Erkrankung, die überwiegend junge Erwachsene betrifft und zu bleibender Behinderung führen kann. Obwohl die Ätiologie der MS noch immer unbekannt ist, haben die vergangenen 10 Jahre beträchtliche Erfolge im Verständnis der zugrunde liegenden Pathophysiologie gebracht. Während die MS als Prototyp einer entzündlichen Autoimmunerkrankung des zentralen Nervensystems (ZNS) angesehen wird, unterstreichen jüngste Daten die Wichtigkeit primärer und sekundärer neurodegenerativer Mechanismen. Die Zulassung des ersten monoklonalen Antikörpers in der neurologischen Therapie, Natalizumab (Tysabri®), verdeutlicht die rasante Weiterentwicklung im Feld. Neuere Behandlungsstrategien zielen insbesondere auch darauf ab, axonalen Schaden zu begrenzen (Axon-/Neuroprotektion) und/oder die Remyelinisierung zu fördern. Der Übersichtsartikel referiert neue Erkenntnisse in der Pathophysiologie der MS; im 2. Teil werden die wichtigsten laufenden oder kürzlich abgeschlossenen klinischen Therapiestudien zusammengestellt.

Aboul-Enein F, Bauer J, Klein M et al. (2004) Selective and antigen-dependent effects of myelin degeneration on central nervous system inflammation. J Neuropathol Exp Neurol 63: 1284–1296PubMed

Abrams JR, Lebwohl MG, Guzzo CA et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243–1252PubMed

Acha-Orbea H, Mitchell DJ, Timmermann L et al. (1988) Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54: 263–273PubMed

Achiron A, Lavie G, Kishner I et al. (2004) T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 113: 155–160PubMed

Agnello D, Bigini P, Villa P et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952: 128–134PubMed

Ahrens N, Salama A, Haas J (2001) Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 248: 713–714PubMed

Alegre ML, Sattar HA, Herold KC et al. (1994) Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 57: 1786–1794PubMed

Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6: 205–217PubMed

Andersen O, Lycke J, Tollesson PO et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895–900PubMed

10.

Antel JP, Bar-Or A (2003) Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med 349: 107–109PubMed

11.

Archelos JJ, Hartung HP (2000) Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci 23: 317–327PubMed

12.

Arroyo AG, Yang JT, Rayburn H, Hynes RO (1996) Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 85: 997–1008PubMed

13.

Babbe H, Roers A, Waisman A et al. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393–404PubMed

14.

Baecher-Allan C, Hafler DA (2004) Suppressor T cells in human diseases. J Exp Med 200: 273–276PubMed

15.

Baker D, Pryce G, Croxford JL et al. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404: 84–87PubMed

16.

Bar-Or A, Antel J, Bodner CA (2006) Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Neurology [Suppl 66]: A62–A62

17.

Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55: 458–468PubMed

18.

Bechtold DA, Kapoor R, Smith KJ (2004) Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55: 607–616PubMed

19.

Beeton C, Wulff H, Barbaria J et al. (2001) Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 98: 13942–13947PubMed

20.

Ben-Nun A, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur J Immunol 11: 949–952PubMed

21.

Benoist C, Mathis D (2001) Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2: 797–801PubMed

22.

Berger T, Rubner P, Schautzer F et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139–145PubMed

23.

Bielekova B, Catalfamo M, Reichert-Scrivner S et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941–5946PubMed

24.

Bielekova B, Goodwin B, Richert N et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167–1175PubMed

25.

Bielekova B, Lincoln A, McFarland H, Martin R (2000) Therapeutic potential of phosphodiesterase-4 and −3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 164: 1117–1124PubMed

26.

Bielekova B, Richert N, Howard T et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 101: 8705–8708PubMed

27.

Bisikirska B, Colgan J, Luban J et al. (2005) TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 115: 2904–2913PubMed

28.

Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14: 271–278PubMed

29.

Black JA, Dib-Hajj S, Baker D et al. (2000) Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci U S A 97: 11598–11602PubMed

30.

Blanco Y, Saiz A, Carreras E, Graus F (2005) Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol 4: 54–63PubMed

31.

Bolton C, Paul C (1997) MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282: 397–402PubMed

32.

Boneberg EM, Hartung T (2002) Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation. Eur J Immunol 32: 1717–1725PubMed

33.

Bothwell M (1995) Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 18: 223–253PubMed

34.

Bourdette DN, Whitham RH, Chou YK et al. (1994) Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 152: 2510–2519PubMed

35.

Bowen JD, Petersdorf SH, Richards TL et al. (1998) Phase I-Study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 64: 339–346PubMed

36.

Brand-Schieber E, Werner P (2004) Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp Neurol 189: 5–9PubMed

37.

Brinkmann V, Davis MD, Heise CE et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453–21457PubMed

38.

Brok HP, Meurs M van, Blezer E et al. (2002) Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 169: 6554–6563PubMed

39.

Brundula V, Rewcastle NB, Metz LM et al. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297–1308PubMed

40.

Brunmark C, Runstrom A, Ohlsson L et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130: 163–172PubMed

41.

Budde K, Schmouder RL, Brunkhorst R et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13: 1073–1083PubMed

42.

Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20: 29–53PubMed

43.

Cepok S, Zhou D, Srivastava R et al. (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115: 1352–1360PubMed

44.

Chang A, Tourtellotte WW, Rudick R, Trapp BD (2002) Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346: 165–173PubMed

45.

Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610–621PubMed

46.

Chen BJ, Morris RE, Chao NJ (2000) Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant 6: 529–536PubMed

47.

Chitnis T, Imitola J, Khoury SJ (2005) Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord 5: 11–26PubMed

48.

Chunduru SK, Sutherland RM, Stewart GA et al. (1996) Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. J Immunol 156: 4940–4945PubMed

49.

Ciric B, Howe CL, Paz Soldan M et al. (2003) Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 13: 608–616PubMedCrossRef

50.

Clements JM, Cossins JA, Wells GM et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74: 85–94PubMed

51.

Cohen J (1995) IL-12 deaths: explanation and a puzzle. Science 270: 908PubMed

52.

Coles AJ, Wing MG, Molyneux P et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296–304PubMed

53.

Columba-Cabezas S, Serafini B, Ambrosini E et al. (2002) Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 130: 10–21PubMed

54.

Craner MJ, Damarjian TG, Liu S et al. (2005) Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49: 220–229PubMed

55.

Craner MJ, Lo AC, Black JA, Waxman SG (2003) Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 126: 1552–1561PubMed

56.

Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23: 127–159PubMed

57.

Dello Russo C, Gavrilyuk V, Weinberg G et al. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278: 5828–5836

58.

Delorenze GN, Munger KL, Lennette ET et al. (2006) Epstein-Barr Virus and Multiple Sclerosis: Evidence of Association From a Prospective Study With Long-term Follow-up. Arch Neurol 63: 839–844PubMed

59.

Diab A, Deng C, Smith JD et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 168: 2508–2515PubMed

60.

Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404–410PubMed

61.

Dyke HJ, Montana JG (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11: 1–13PubMed

62.

Ehrenreich H, Aust C, Krampe H et al. (2004) Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 19: 195–206PubMed

63.

Elices MJ (2002) BX-471 Berlex. Curr Opin Investig Drugs 3: 865–869PubMed

64.

Engelhardt B, Briskin MJ (2005) Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol 35: 2268–2273PubMed

65.

Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26: 485–495PubMed

66.

Farrell R, Heaney D, Giovannoni G (2005) Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 10: 797–816PubMed

67.

Fassas A, Passweg JR, Anagnostopoulos A et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249: 1088–1097PubMed

68.

Ferrante P, Fusi ML, Saresella M et al. (1998) Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 160: 1514–1521PubMed

69.

Filippi M (2002) The role of magnetic resonance imaging in the assessment of patients with established multiple sclerosis. Neurol Sci 23: 89–90PubMed

70.

Filippi M, Rovaris M, Rice GP et al. (2000) The effect of cladribine on T(1) ‚black hole‘ changes in progressive MS. J Neurol Sci 176: 42–44PubMed

71.

Fontoura P, Garren H, Steinman L (2005) Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol 24: 415–446PubMed

72.

Fox RJ, Ransohoff RM (2004) New directions in MS therapeutics: vehicles of hope. Trends Immunol 25: 632–636PubMed

73.

Frauwirth KA, Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109: 295–299PubMed

74.

Friese MA, Montalban X, Willcox N et al. (2006) The value of animal models for drug development in multiple sclerosis. Brain 129: 1940–1952PubMed

75.

Frohman EM, Brannon K, Racke MK, Hawker K (2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27: 80–83PubMed

76.

Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 354: 942–955PubMed

77.

Fujimoto T, Sakoda S, Fujimura H, Yanagihara T (1999) Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 95: 35–42PubMed

78.

Fujino M, Funeshima N, Kitazawa Y et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305: 70–77PubMed

79.

Gately MK, Renzetti LM, Magram J et al. (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495–521PubMed

80.

Genc K, Genc S, Baskin H, Semin I (2006) Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res 55: 33–38PubMed

81.

Genc S, Koroglu TF, Genc K (2004) Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 22: 105–119PubMed

82.

Germain RN, Stefanova I (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17: 467–522PubMed

83.

Giuliani F, Fu SA, Metz LM, Yong VW (2005) Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 165: 83–91PubMed

84.

Gold R, Havrdova E, Kappos L et al. (2006) Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting mutiple sclerosis: results of a phase 2 study. J Neurol 253: 144

85.

Gonsette RE, Dubois B (2004) Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J Neurol Sci 223: 81–86PubMed

86.

Goodkin DE, Shulman M, Winkelhake J et al. (2000) A phase I trial of solubilized DR2: MBP84–102 (AG284) in multiple sclerosis. Neurology 54: 1414–1420PubMed

87.

Gordon EJ, Myers KJ, Dougherty JP et al. (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62: 153–160PubMed

88.

Greter M, Heppner FL, Lemos MP et al. (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11: 328–334PubMed

89.

Hickey WF, Kimura H (1988) Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239: 290–292PubMed

90.

Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A [Suppl 2] 101: 14599–14606

91.

Hohlfeld R, Wiendl H (2001) The ups and downs of multiple sclerosis therapeutics. Ann Neurol 49: 281–284PubMed

92.

Howard LM, Kohm AP, Castaneda CL, Miller SD (2005) Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr Drug Targets Inflamm Allergy 4: 205–216PubMed

93.

Howell MD, Winters ST, Olee T et al. (1989) Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246: 668–670PubMed

94.

Huitinga I, Ruuls SR, Jung S et al. (1995) Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol 100: 344–351PubMedCrossRef

95.

Jiang H, Kashleva H, Xu LX et al. (1998) T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells. Proc Natl Acad Sci U S A 95: 4533–4537PubMed

96.

Jonsson S, Andersson G, Fex T et al. (2004) Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47: 2075–2088PubMed

97.

Kalkers NF, Barkhof F, Bergers E et al. (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 8: 532–533PubMed

98.

Kappos L, Antel J, Comi G et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124–1140PubMed

99.

Kappos L, Barkhof F, Desmet A (2005) The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J Neurol [Suppl 42] 252: 46–46

100.

Kappos L, Comi G, Panitch H et al. (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6: 1176–1182PubMed

101.

Kappos L, Miller DH, MacManus DG et al. (2006) Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. J Neurol 253: 27

102.

Kawai T, Andrews D, Colvin RB et al. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114

103.

Keegan M, Konig F, McClelland R et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579–582PubMed

104.

Keeley KA, Rivey MP, Allington DR (2005) Natalizumab for the treatment of multiple sclerosis and Crohn’s disease. Ann Pharmacother 39: 1833–1843PubMed

105.

Kerschensteiner M, Stadelmann C, Dechant G et al. (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53: 292–304PubMed

106.

Killestein J, Olsson T, Wallstrom E et al. (2002) Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol 51: 467–474PubMed

107.

Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369–374PubMed

108.

Kleinschnitz C, Schroeter M, Jander S, Stoll G (2004) Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Brain Res Mol Brain Res 131: 73–78PubMed

109.

Klotz L, Schmidt M, Giese T et al. (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175: 4948–4955PubMed

110.

Kobata T, Azuma M, Yagita H, Okumura K (2000) Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2: 74–80PubMed

111.

Kohm AP, Williams JS, Bickford AL et al. (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174: 4525–4534PubMed

112.

Konno H, Yamamoto T, Iwasaki Y et al. (1989) Ia-expressing microglial cells in experimental allergic encephalomyelitis in rats. Acta Neuropathol (Berl) 77: 472–479

113.

Korn T, Magnus T, Toyka K, Jung S (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion. J Leukoc Biol 76: 950–960PubMed

114.

Kornek B, Storch MK, Bauer J et al. (2001) Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 124: 1114–1124PubMed

115.

Krumbholz M, Theil D, Derfuss T et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195–200PubMed

116.

Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399–1402PubMed

117.

Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7: 115–121PubMed

118.

Lebwohl M, Tyring SK, Hamilton TK et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004–2013PubMed

119.

Lennon VA, Kryzer TJ, Pittock SJ et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473–477PubMed

120.

Li W, Maeda Y, Yuan RR et al. (2004) Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 56: 767–777PubMed

121.

Lim ET, Berger T, Reindl M et al. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 11: 492–494PubMed

122.

Lindsey JW, Hodgkinson S, Mehta R et al. (1994) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 36: 183–189PubMed

123.

Linsley PS, Brady W, Urnes M et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561–569PubMed

124.

Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90: 3566–3571PubMed

125.

Lovett-Racke AE, Bittner P, Cross AH et al. (1998) Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 101: 1797–1804PubMed

126.

Lublin F (1999) A phase II trial of anti-CD11/CD18 monoclonal antibody in acute exacerbations of MS. Neurology 52 [Suppl 2]

127.

Lucchinetti C, Bruck W, Parisi J et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707–717PubMed

128.

Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55: 300–309PubMed

129.

Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F (2004) Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 11–23PubMed

130.

Magnus T, Schreiner B, Korn T et al. (2005) Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 25: 2537–2546PubMed

131.

Mancardi GL, Saccardi R, Filippi M et al. (2001) Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57: 62–68PubMed

132.

Mandala S, Hajdu R, Bergstrom J et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346–349PubMed

133.

Marecki S, Kirkpatrick P (2004) Efalizumab. Nat Rev Drug Discov 3: 473–474PubMed

134.

Marracci GH, McKeon GP, Marquardt WE et al. (2004) Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res 78: 362–370PubMed

135.

Matloubian M, Lo CG, Cinamon G et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355–360PubMed

136.

McDonald WI, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127PubMed

137.

Meden H, Mielke S, Marx D et al. (1997) Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 17: 3075–3077PubMed

138.

Meinl E, Weber F, Drexler K et al. (1993) Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 92: 2633–2643PubMedCrossRef

139.

Metz LM, Zhang Y, Yeung M et al. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55: 756PubMed

140.

Miller DH, Khan OA, Sheremata WA et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15–23PubMed

141.

Monson NL, Cravens PD, Frohman EM et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62: 258–264PubMed

142.

Morini M, Roccatagliata L, Dell’Eva R et al. (2004) Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 146–153PubMed

143.

Muller H, Hofer S, Kaneider N et al. (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35: 533–545PubMed

144.

Muraro PA, Douek DC, Packer A et al. (2005) Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201: 805–816PubMed

145.

Nash RA, Bowen JD, McSweeney PA et al. (2003) High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102: 2364–2372PubMed

146.

Nashmi R, Fehlings MG (2001) Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev 38: 165–191PubMed

147.

Neuhaus O, Strasser-Fuchs S, Fazekas F et al. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59: 990–997PubMed

148.

Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25: 313–319PubMed

149.

Niino M, Bodner C, Simard ML et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748–754PubMed

150.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938–952PubMed

151.

Noseworthy JH, Wolinsky JS, Lublin FD et al. (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators [see comments]. Neurology 54: 1726–1733PubMed

152.

O’Connor PW, Li D, Freedman MS (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894–900

153.

Paemen L, Martens E, Norga K et al. (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52: 105–111PubMed

154.

Paolillo A, Coles AJ, Molyneux PD et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53: 751–757PubMed

155.

Pershadsingh HA (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13: 215–228PubMedCrossRef

156.

Pershadsingh HA, Heneka MT, Saini R et al. (2004) Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 1: 3PubMed

157.

Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67–70PubMed

158.

Platten M, Steinman L (2005) Multiple sclerosis: trapped in deadly glue. Nat Med 11: 252–253PubMed

159.

Polman C, Barkhof F, Sandberg-Wollheim M et al. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64: 987–991PubMed

160.

Polman CH, O’Connor PW, Havrdova E et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910PubMed

161.

Pryce G, Ahmed Z, Hankey DJ et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126: 2191–2202PubMed

162.

Putheti P, Pettersson A, Soderstrom M et al. (2004) Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J Clin Immunol 24: 155–161PubMed

163.

Qin Y, Duquette P, Zhang Y et al. (2003) Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 83: 1081–1088PubMed

164.

Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8: 1275PubMed

165.

Rice GP, Filippi M, Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI-Study Group. Neurology 54: 1145–1155PubMed

166.

Rizvi SA, Bashir K (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 12 [Suppl 6] (63): 47–54

167.

Rumbach L, Racadot E, Armspach JP et al. (1996) Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Mult Scler 1: 207–212PubMed

168.

Rutella S, Zavala F, Danese S et al. (2005) Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 175: 7085–7091PubMed

169.

Saccardi R, Mancardi GL, Solari A et al. (2005) Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105: 2601–2607PubMed

170.

Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345–352PubMed

171.

Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19: 225–252PubMed

172.

Samijn JP, Boekhorst PA te, Mondria T et al. (2006) Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 77: 46–50PubMed

173.

Saruhan-Direskeneli G, Weber F, Meinl E et al. (1993) Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. Eur J Immunol 23: 530–536PubMed

174.

Scheinfeld N (2006) Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5: 197–209PubMed

175.

Schimrigk S, Brune N, Hellwig K et al. (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13: 604–610PubMed

176.

Schneider-Gold C, Hartung HP, Gold R (2006) Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34: 284–291PubMed

177.

Scott GS, Spitsin SV, Kean RB et al. (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99: 16303–16308PubMed

178.

Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35: 7S–14SPubMed

179.

Sellebjerg F, Sorensen TL (2003) Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 61: 347–355PubMed

180.

Sicotte NL, Giesser BS, Tandon V (2006) A pilot study of testosterone treatment for men with relapsing remitting multiple sclerosis. Neurology 66: A30

181.

Sicotte NL, Liva SM, Klutch R et al. (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52: 421–428PubMed

182.

Sidiropoulos PI, Boumpas DT (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391–397PubMed

183.

Simmons DL, Buckley CD (2005) Some new, and not so new, anti-inflammatory targets. Curr Opin Pharmacol 5: 394–397

184.

Sipe JC (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5: 721–727PubMed

185.

Sipe JC, Romine JS, Koziol J et al. (1997) Cladribine improves relapsing-remitting MS: a double blind placebo controlled study. Neurology 48: A340

186.

Sipe JC, Romine JS, Koziol JA et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis [see comments]. Lancet 344: 9–13PubMed

187.

Sjoo F, Hassan Z, Abedi-Valugerdi M et al. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 34: 115–121PubMed

188.

Smilek DE, Wraith DC, Hodgkinson S et al. (1991) A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 88: 9633–9637PubMed

189.

Sospedra M, Martin R (2005) Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 24: 393–413PubMed

190.

Steinman L (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4: 510–518PubMed

191.

Steinman L (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2: 762–764.PubMed

192.

Storer PD, Xu J, Chavis J, Drew PD (2005) Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 161: 113–122PubMed

193.

Stuve O, Youssef S, Weber MS et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116: 1037–1044PubMed

194.

Suntharalingam G, Perry MR, Ward S et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018–1028PubMed

195.

Thoenen H, Sendtner M (2002) Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 5 [Suppl]: 1046–1050

196.

Trebst C, Stangel M (2006) Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Curr Pharm Des 12: 241–249PubMed

197.

Tubridy N, Behan PO, Capildeo R et al. (1999) The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS. Neurology 53: 466–472PubMed

198.

Utset TO, Auger JA, Peace D et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29: 1907–1913PubMed

199.

Van Assche G, Van Ranst M, Sciot R et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353: 362–368

200.

Van der Aa A, Hellings N, Medaer R et al. (2003) T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 131: 155–168

201.

Oosten BW van, Barkhof F, Truyen L et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531–1534PubMed

202.

Oosten BW van, Lai M, Barkhof F et al. (1996) A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Mult Scler 1: 339–342PubMed

203.

Vandenbark AA, Chou YK, Whitham R et al. (1996) Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Medicine 2: 1109–1115PubMed

204.

Vennekamp J, Wulff H, Beeton C et al. (2004) Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65: 1364–1374PubMed

205.

Vermersch P, Waucquier N, Bourteel H (2004) Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and Mycophenolate mofetil (Cellcept): Results of a phase II clinical trial. Neurology 62: A259

206.

Vianna-Jorge R, Suarez-Kurtz G (2004) Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders? BioDrugs 18: 329–341PubMed

207.

Villoslada P, Hauser SL, Bartke I et al. (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191: 1799–1806PubMed

208.

Vincenti F, Kirkman R, Light S et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338: 161–165PubMed

209.

Vollmer T, Key L, Durkalski V et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607–1608PubMed

210.

Waldmann H (1989) Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 7: 407–444PubMed

211.

Warren KG, Catz I, Wucherpfennig KW (1997) Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 152: 31–38PubMed

212.

Waxman SG, Craner MJ, Black JA (2004) Na+ channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 25: 584–591PubMed

213.

Weiner HL, Mackin GA, Matsui M et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321–1324PubMed

214.

Weinshenker BG, Bass B, Karlik S et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41: 1047–1052PubMed

215.

Weissert R, Wiendl H, Pfrommer H et al. (2003) Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J Neuroimmunol 144: 28–37PubMed

216.

Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169–180PubMed

217.

Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16: 183–200PubMed

218.

Wiendl H, Kieseier BC, Weissert R et al. (2007) Treatment of active secondary progressive multiple sclerosis with treosulfan: an open label pilot study. J Neurol (in press)

219.

Willenborg DO, Staykova MA, Miyasaka M (1996) Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 157: 1973–1980PubMed

220.

Yadav V, Marracci G, Lovera J et al. (2005) Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 11: 159–165PubMed

221.

Yong VW, Wells J, Giuliani F et al. (2004) The promise of minocycline in neurology. Lancet Neurol 3: 744–751PubMed

222.

Yousry TA, Major EO, Ryschkewitsch C et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924–933PubMed

223.

Youssef S, Stuve O, Patarroyo JC et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78–84PubMed

224.

Zajicek J, Fox P, Sanders H et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526PubMed

225.

Zang YC, Hong J, Rivera VM et al. (2000) Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 164: 4011–4017PubMed

226.

Zipp F, Hartung HP, Hillert J et al. (2005) Blockade of chemokine receptor in multiple sclerosis patients. Mult Scler 11: S13

227.

Zipp F, Krammer PH, Weller M (1999) Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 20: 550–554PubMed

Titel: Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen
verfasst von: C. Kleinschnitz
S.G. Meuth
B.C. Kieseier
Prof. Dr. H. Wiendl
Publikationsdatum: 01.08.2007
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 8/2007
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-007-2261-9

Neu in den Fachgebieten Neurologie und Psychiatrie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

Aspekte der Schmerzbehandlung

Rete mirabile bei segmentaler Agenesie der A. carotis interna

Neurologische Prognose und Therapie nach kardiopulmonaler Reanimation

Klinische und diagnostische Charakteristika des Wurzelsyndroms Th1

Begutachtung der Tagesschläfrigkeit bei neurologischen Erkrankungen und dem obstruktiven Schlafapnoesyndrom (OSAS)

Neurologie in Deutschland – 100 Jahre DGN

Neu in den Fachgebieten Neurologie und Psychiatrie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich